Iprivask desirudin: Phase IIIb data

In the open-label Phase IIIb PREVENT-HIT trial in 16 patients with clinically suspected HIT, no cases of thrombosis or major bleeding occurred in patients treated with fixed doses of 15 or 30 mg subcutaneous Iprivask every 12 hours (n=8) compared with 1 case of thrombosis and 2 occurrences of major bleeding in patients treated with adjusted-dose, IV argatroban (n=8). Additionally, Iprivask required dose-adjustment 1 time during the entire study, whereas argatroban required dose-adjustment an average of 3.8 times per patient. The mean cost per patient for the entire course of treatment was $1,750 for Iprivask compared to $8,250 for argatroban. Data were presented at the Hemophilia and Thrombosis Research Society meeting in Chicago. ...